Aclaris Therapeutics Inc. (NASDAQ: ACRS) has initiated a phase 1b proof-of-concept trial for ATI-052, its investigational bispecific antibody, in patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE